查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1837190

兽医分子诊断市场按产品、技术、动物类型、疾病类型和最终用户划分－2025-2032年全球预测

Veterinary Molecular Diagnostic Market by Product, Technology, Animal Type, Disease Type, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，兽医分子诊断市场规模将成长 13.0176 亿美元，复合年增长率为 9.44%。

关键市场统计数据
基准年 2024 6.324亿美元
预计年份：2025年 6.9227亿美元
预测年份 2032 13.176亿美元
复合年增长率 (%) 9.44%

在兽医分子诊断领域，面对快速的技术进步和不断变化的业务挑战，为决策者提供必要的背景资讯。

兽医分子诊断领域正处于快速技术创新与兽医医疗保健产业对准确、及时检测日益增长的需求交汇点。聚合酵素链锁反应)、数位和等温扩增技术、微阵列平台以及高通量定序的最新进展，正在拓展检测传染性病原体、鑑定遗传疾病以及支持兽医临床肿瘤治疗的可能性。同时，从学术机构和研究中心到诊断实验室和临床动物医院，终端使用者群体不断扩大，这正在建立一个更复杂的生态系统，在这个系统中，诊断必须具备稳健性、成本效益，并与临床工作流程无缝衔接。

随着诊断能力的不断发展，相关人员面临着动态的监管环境、复杂的供应链以及跨部门合作。曾经透过成熟经销商稳定采购的仪器和耗材，如今受到全球贸易动态和供应商整合的影响；同时，用于将原始数据转化为可执行临床决策的软体和解读服务也变得日益重要。本导言强调了技术选择、营运能力和市场服务之间策略协调的必要性，为后续分析组装。透过将读者置于这一动态环境中，接下来的叙述将揭示变革性趋势、监管压力、细分市场主导的机会，并提出应对近期挑战和加速在不同动物物种和医疗保健环境中推广应用的建议措施。

总的来说，本节为决策者和研究人员评估风险、确定投资优先顺序以及製定干预措施以利用分子诊断改善动物健康并管理营运复杂性奠定了基础。

检验将彻底改变动物分子诊断技术开发、检验和交付方式的关键技术、监管和营运变革。

在技​​术融合、临床需求变化以及供应链和报销模式面临的机构压力等因素的共同推动下，兽医分子诊断领域正经历一场变革。次世代定序仪正从小众研究应用转向病原体发现和抗菌药物抗药性分析等更常规的应用，而即时PCR和数位PCR仍然是标靶、高灵敏度检测的主力。同时，等温扩增技术和可携式平台正推动水产养殖、畜牧业和野生动物监测领域的照护现场和现场诊断，从而支持更快的疫情应对和畜群层面的决策。这些变革得益于生物资讯学和云端基础解读技术的进步，缩短了周转时间，并使复杂分析的普及化。

试剂供应商和仪器提供者的整合、对诊断验证和资料完整性日益严格的监管审查，以及终端用户对包含检测、仪器和解读服务的捆绑式解决方案的需求不断增长，都在重塑市场动态。此外，多检体物检测组合的日益复杂以及对跨平台相容性的需求，也推动了对开放式架构仪器和检验耗材的重视。因此，检测开发商、平台提供者和研发机构之间的伙伴关係正成为加快产品上市速度和确保临床效用的策略要务。

简而言之，该行业正从孤立的技术部署转向以服务为导向的整合模式，强调数据驱动的诊断、营运弹性以及可扩展的工作流程。相关人员，将在日益复杂、以结果为导向的动物保健市场中获得竞争优势。

分析2025年美国关税对兽医分子诊断供应链的多方面营运与采购影响

到2025年，美国关税政策的累积变化将对兽医分子诊断供应链、筹资策略和成本结构产生多方面的影响。进口设备和某些试剂关税的提高正在加剧实验室采购预算的压力，并影响高容量设备和一次性耗材的采购决策。因此，一些实验室和兽医网路正在加快在地化策略的实施，并寻求国内经销商和区域製造合作伙伴，以降低贸易摩擦带来的风险并避免库存波动。

这些贸易措施也促使买家重新评估PCR仪、定序仪和辅助自动化设备的总拥有成本，考虑到前置作业时间延长、维护合约需要重新协商以及备件成本增加等因素。对于试剂密集型工作流程而言，原料和特殊酵素的关税促使企业更加重视供应多元化、库存避险以及与能够确保供应连续性的供应商签订更长的合约期限。同时，对跨境实体运输依赖性较低的软体和解读服务已成为一种低关税途径，可为诊断服务增值并抵消硬体相关的成本压力。

监管和采购团队已采取应对措施，包括重新谈判供应商合约、寻求与区域製造商建立策略伙伴关係关係，以及优先选择可相容多种有效耗材的开放平台仪器，以降低单一供应商风险。同时，实验室也在增加对工作流程效率和多重检测的投资，以降低每次检测的试剂消费量。总而言之，这些因应措施正在重塑采购模式，促进更具协作性的供应商关係，并加速采用能够在贸易保护主义盛行的环境下平衡成本、性能和供应链安全的弹性采购惯例。

解锁跨产品、技术、动物类型、疾病和最终用户环境的详细细分，以指导有针对性的诊断策略和开发。

对市场区隔的深入理解揭示了需求的来源、技术选择如何与物种和疾病优先事项相交，以及哪些终端使用者环境将推动技术的持续应用。产品包括耗材和试剂、仪器以及软体和服务。耗材和试剂可以理解为酵素製剂、检测试剂套件以及对检测灵敏度和特异性至关重要的探针和引子；而仪器则根据不同的通量和应用需求进行分类，从PCR仪到定序仪。软体和服务日益成为连接各方的纽带，实现数据解读、工作流程编配和远距离诊断。

从技术角度来看，传统PCR、数位PCR、等温扩增、微阵列、次世代定序和即时PCR各有其独特的价值提案。次世代定序仪本身涵盖了Illumina、Ion Torrent和Oxford Nanopore等多种技术，每种技术在读长、通量和现场应用性方面各有优劣。这些技术选择与动物类型密切相关：水产养殖中鱼贝类的检测需要稳健可靠且通常可现场应用的检测方法；禽类检测优先考虑快速牛检测以保护畜群健康；伴侣动物诊断，特别是犬猫的诊断，侧重于遗传疾病筛检和肿瘤检测；则是研究动物

此外，野生动物检测需要以广泛发现和保护病原体为重点的基因分析。疾病细分进一步细化了检验和开发重点：遗传性疾病需要高保真度基因型鉴定检测，感染疾病需要灵敏快速地检测细菌、真菌、寄生虫和病毒等病原体，而肿瘤则需要能够分析肿瘤相关变异的检测方法。最后，最终用户——学术机构、诊断中心、参考实验室、研究机构以及兽医诊所和临床诊所——在通量、监管要求和采用复杂工作流程的意愿方面各不相同。学术研究机构通常会试验创新技术和生物资讯学方法，参考实验室优先考虑具有严格品质控制的标准化高通量检测，而临床兽医诊所则寻求能够快速提供可解释结果并指导患者照护的整合解决方案。总而言之，这些细分为产品开发、检验策略和市场推广优先顺序提供了蓝图，使技术能力与每个使用者群体的营运需求相匹配。

绘製美洲、欧洲、中东和非洲以及亚太地区的需求驱动因素、基础设施成熟度和监管差异图，为部署策略提供资讯。

区域动态在塑造兽医分子诊断的需求、监管方式和部署模式方面发挥着至关重要的作用。在美洲，成熟的兽医服务市场、强大的研究基础设施以及先进的畜牧和伴侣动物护理生态系统，推动了对高通量平台、专用试剂和整合软体解决方案的需求，这些解决方案既支持临床决策，也支持流行病学监测。此外，该地区庞大的私人兽医诊所和参考文献实验室基础，也有利于早期采用针对伴侣动物和畜牧物种的新型检测方法和伴侣诊断技术。

在欧洲、中东和非洲，不同的法规环境和实验室能力水准导致了不同的应用模式。西欧和北欧市场倾向于采用验证标准更为严格的复杂技术，而中东和非洲部分地区则优先考虑经济高效、可现场使用的诊断方法，以管控通用动物和感染疾病的风险。能力建构和官民合作关係，以及旨在加强实验室网路和数据共用框架的合作倡议，正在加速多个次区域分子诊断技术的部署。

亚太地区兽医服务、大规模水产养殖业和密集畜牧生产体系的快速发展，推动了可扩展诊断和监测工具的需求。该地区各国正投资于定序和多重检测能力，以应对疾病爆发并提升食品安全。区域製造能力和不断增长的区域试剂供应链也在逐步建立，以减轻跨境贸易中断的影响，并支援大规模检测的快速反应。这些区域差异凸显了根据区域的具体临床需求、基础设施成熟度和政策重点，客製化产品系列、监管策略和分销模式的重要性。

评估仪器供应商、试剂製造商、检测开发商以及软体和服务供应商的竞争动态和伙伴关係差异化

兽医分子诊断领域的竞争格局呈现出多元化的态势，既有成熟的平台供应商，也有专注于特定应用和现场部署技术的灵活新兴企业。仪器製造商持续投资于开放平台相容性，以确保耗材和服务收入来源；试剂供应商则着重提供检验的套件和品管材料，以促进实验室资格认证和日常应用。同时，软体供应商和服务供应商透过分析演算法、解读演算法以及云端报告来减轻终端用户实验室和临床医生的负担，从而实现差异化竞争。

检测开发商与设备供应商之间的共同开发契约能够加快验证週期，并促成对诊断中心和参考实验室更具吸引力的捆绑式产品。与学术和研究机构的合作通常能够支持检测设计和生物资讯流程的创新，从而产生早期验证数据，降低商业性上市的风险。专注于照护现场和可携式定序的新兴企业凭藉其在水产养殖、畜牧业现场监测和野生动物监测领域分散检测的潜力而日益受到关注，促使现有企业采取战略应对措施，以增强产品平臺。

最后，透过品质、合规性和客户支援实现差异化变得越来越重要。买家优先考虑能够提供全面培训、完善的品质控製材料和快速服务回应以最大限度减少停机时间的合作伙伴。投资于生命週期服务、远端故障排除和以证据支持的性能声明的公司，更有可能与诊断中心和兽医医院网路签订长期合约。在这种竞争激烈的环境中，能够获得最持久价值的公司将依赖周密的联盟构建、清晰的检验路径以及对最终用户体验的关注。

为产业领导者提供优先且切实可行的策略，以增强韧性、加速临床应用并扩大诊断在动物健康领域的影响力。

产业领导者应采取一系列切实可行的优先行动，以增强兽医分子诊断的韧性，加速其应用，并提升其临床影响力。首先，在设计产品系列，应充分考虑互通性，透过在多种仪器平台上检验检测方法，并确保其与广泛使用的资料管理系统相容来实现。其次，应投资区域性生产和战略供应商协议，以确保关键试剂和酵素的供应，同时实施库存优化策略，以应对短期贸易中断的影响。

第三，我们将透过针对重点疾病组合和物种特异性适应症产生可靠的效能数据，使我们的监管和临床检验策略与目标终端使用者的需求保持一致。我们将儘早与参考实验室和学术合作伙伴合作，共同开发证据包，以加速诊断中心和临床机构的采用。第四，我们将透过捆绑软体、解读分析和培训计画来增强我们的服务，从而降低兽医医院和诊所采用分子诊断的运作门槛。第五，我们将采用模组化的市场推广模式，将高通量参考实验室解决方案与适用于水产养殖、畜牧业和野生动物监测的小型化、现场即用型平台结合。

最后，在设计云端基础的报告系统时，应优先考虑资料管治、网路安全和互通性标准，并维持关于验证、品管和供应链溯源的透明沟通。透过实施这些有针对性的措施，企业可以减少商业摩擦，支持循证应用，并与实验室和临床网络建立长期伙伴关係，从而加速分子诊断在兽医医疗保健领域的广泛应用。

描述一种严谨的混合方法研究途径，该方法整合了第一手访谈、技术文献和供应链基准，以检验研究结果。

本研究整合了定性和定量方法，旨在对兽医分子诊断领域进行稳健且基于实证的理解。调查方法首先对同行评审文献、监管指南、技术白皮书和行业出版物进行了全面回顾，以确定基准定义、技术能力和检验标准。在此基准上，主要研究包括对实验室主任、兽医临床医生、检测开发人员、仪器工程师和采购专家进行结构化访谈，以深入了解工作流程、应用障碍和采购行为等方面的实际问题。

此外，我们对产品和技术细分进行了系统性梳理，以使耗材类别、设备类型和软体产品与特定物种和疾病的用例相匹配。我们将一手资讯与二手资讯和专家回馈进行比较，并进行了交叉检验，以消除差异并确保内部一致性。分析方法包括：对定性输入进行主题综合分析；对工作流程和用例进行基准基准化分析，以评估操作适用性；以及对供应链进行分析，以识别风险节点和缓解策略。

需要指出的是，本研究存在一些限制。不断变化的贸易政策、快速的平台创新以及局部监管政策的调整都可能在资料收集后改变市场动态，因此相关人员应将研究结果视为决策支援框架，而非静态预测。为确保透明度，我们记录了调查方法、资料来源、受访者概况以及检验步骤，以便读者评估具体研究结果在其自身情境中的适用性。这种混合方法为兽医分子诊断领域的策略决策、产品规划和监管推广提供了基础。

总结全文，重点在于技术创新、营运韧性和协作伙伴关係关係对于实现持续诊断影响的重要性。

兽医分子诊断的发展轨迹呈现出技术日益复杂、数据主导服务整合度不断提高以及采购和监管环境不断演变的特点，这些因素共同为相关人员带来了机会和挑战。目前，各方正朝着兼顾分析绩效和营运可行性的解决方案迈进，力求无论采用何种技术或动物类型，都能为临床照护、监测和研究提供更快、更准确的结果。同时，供应链的脆弱性和关税相关的压力要求制定策略规划，以确保检测的连续性，并在不同的终端用户环境中维持服务水准。

因此，投资于互通平台、多元化供应链和循证检验的机构将更有利于支持分子诊断在兽医学领域日益扩展的作用。同样重要的是，他们致力于终端使用者培训、品质保证和资料管理，从而将分析结果转化为改善动物健康状况的成效。永续发展取决于将技术创新与务实的部署策略、强大的伙伴关係以及适应性采购惯例相结合，从而在兽医学领域实现可扩展的高品质诊断服务。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 将次世代定序应用于兽医诊断中的病原体快速检测
  • 扩大照护现场PCR检测在牲畜和伴侣动物现场疾病筛检的应用
  • 在动物健康监测中采用数位PCR技术进行病毒量定量
  • 利用CRISPR的诊断工具进行通用感染疾病的超灵敏检测
  • 开发用于同时检测多种兽医病原体的多重分子检测板
  • 运用人工智慧驱动的数据分析来增强对分子诊断结果的解读
  • 推出一种用于兽医快速分子检测的可携式等温扩增装置
  • 利用分子检测技术发展远距离诊断服务，促进分散式兽医护理
  • 引入分子生物标记用于动物病原体抗菌素抗药性的早期检测
  • 兽医诊断实验室与生物技术公司之间的合作加速了检测方法的开发和检验。

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：按产品分類的动物分子诊断市场

  • 耗材和试剂
    • 酵素
    • 套件
    • 探针和引子
  • 装置
    • PCR设备
    • 序列器
  • 软体和服务

第九章 依技术分類的动物分子诊断市场

  • 常规PCR
  • 数位PCR
  • 等温扩增
  • 微阵列
  • 次世代定序
    • Illumina定序
    • 离子流定序
    • 牛津奈米孔
  • 即时PCR

第十章 依动物类型分類的动物分子诊断市场

  • 水产养殖
    • 鱼
    • 贝类
  • 鸟类
  • 伴侣动物
    • 猫
    • 狗
  • 家畜
    • 牛
    • 家禽
    • 猪
  • 野生动物

第十一章：依疾病类型分類的动物分子诊断市场

  • 遗传性疾病
  • 感染疾病
    • 细菌感染疾病
    • 霉菌感染疾病
    • 寄生虫感染疾病
    • 病毒感染
  • 肿瘤学

第十二章：依最终使用者分類的动物分子诊断市场

  • 学术机构
  • 诊断中心
  • 参考实验室
  • 研究机构
  • 兽医医院和诊所

第十三章：按地区分類的兽医分子诊断市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 动物分子诊断市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国动物分子诊断市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • IDEXX Laboratories, Inc.
    • Thermo Fisher Scientific Inc.
    • Zoetis Inc.
    • QIAGEN NV
    • Bio-Rad Laboratories, Inc.
    • Neogen Corporation
    • Heska Corporation
    • Ceva Sante Animale SA
    • Vetoquinol SA
    • Eurofins Scientific SE
Product Code: MRR-034B50030397

The Veterinary Molecular Diagnostic Market is projected to grow by USD 1,301.76 million at a CAGR of 9.44% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 632.40 million
Estimated Year [2025] USD 692.27 million
Forecast Year [2032] USD 1,301.76 million
CAGR (%) 9.44%

Establishing context for decision-makers amid rapid technological advances and evolving operational challenges in veterinary molecular diagnostics

The veterinary molecular diagnostics field stands at the confluence of rapid technological innovation and intensifying demand for precise, timely testing across animal health sectors. Recent advances in polymerase chain reaction modalities, digital and isothermal amplification techniques, microarray platforms, and high-throughput sequencing have broadened the possibilities for detecting infectious agents, characterizing genetic disorders, and supporting oncology in veterinary practice. Concurrently, an expanding base of end users-from academic institutions and research centers to diagnostic laboratories and clinical veterinary hospitals-has generated a more complex ecosystem where diagnostics must be robust, cost-effective, and integrated with clinical workflows.

As diagnostic capabilities evolve, stakeholders face a shifting landscape of regulatory requirements, supply chain sensitivities, and cross-sector collaborations. Instruments and consumables that once flowed predictably through established distributors are now influenced by global trade dynamics and supplier consolidation, while software and interpretive services are assuming greater importance to translate raw data into actionable clinical decisions. This introduction frames the subsequent analysis by emphasizing the need for strategic alignment between technology selection, operational capacity, and market-facing services. By situating the reader within this dynamic environment, the narrative that follows unpacks transformative trends, regulatory pressures, segmentation-driven opportunities, and recommended actions to navigate near-term disruptions and accelerate adoption across diverse animal types and care settings.

Overall, this section establishes context for decision-makers and researchers to assess risk, prioritize investments, and design interventions that leverage molecular diagnostics to improve animal health outcomes while managing operational complexity.

Examining the pivotal technological, regulatory, and operational shifts reshaping how veterinary molecular diagnostics are developed, validated, and delivered

The landscape of veterinary molecular diagnostics is undergoing transformative shifts driven by technological convergence, changing clinical expectations, and systemic pressures on supply chains and reimbursement models. Next-generation sequencing has transitioned from niche research use into more routine applications for pathogen discovery and antimicrobial resistance profiling, while real-time PCR and digital PCR remain workhorses for targeted, high-sensitivity detection. Simultaneously, isothermal amplification techniques and portable platforms are enabling point-of-care and field diagnostics for aquaculture, livestock, and wildlife surveillance, which supports faster outbreak response and herd-level decision-making. These changes are reinforced by software advances in bioinformatics and cloud-based interpretation that reduce turnaround times and democratize access to complex analyses.

Market dynamics are also being reshaped by consolidation among reagent suppliers and instrumentation providers, heightened regulatory scrutiny of diagnostic validation and data integrity, and growing pressure from end users for bundled solutions that combine assays, instruments, and interpretive services. In addition, the rising complexity of multi-species testing panels and the need for cross-platform compatibility has placed a premium on open architecture instruments and validated consumables. As a result, partnerships between assay developers, platform providers, and research institutions are becoming a strategic imperative to accelerate time-to-market and ensure clinical utility.

In short, the field is shifting from isolated technology deployments toward integrated, service-oriented models that emphasize data-driven diagnostics, operational resilience, and scalable workflows. Stakeholders that anticipate these shifts and align product development, distribution strategies, and customer support accordingly will gain competitive advantage in an increasingly sophisticated and outcome-focused veterinary healthcare market.

Analyzing the multifaceted operational and procurement consequences of United States tariff measures in 2025 on veterinary molecular diagnostics supply chains

Cumulative tariff developments originating in the United States for 2025 have introduced multifaceted impacts on the veterinary molecular diagnostics supply chain, procurement strategies, and cost structures. Tariff-induced increases on imported instruments and certain reagents have pressured laboratory procurement budgets and influenced decisions about where to source high-value capital equipment versus single-use consumables. As a consequence, some laboratories and veterinary networks have accelerated localization strategies, seeking domestic distributors or regional manufacturing partners to reduce exposure to trade friction and avoid inventory volatility.

These trade measures have also prompted buyers to reassess total cost of ownership for PCR instruments, sequencers, and ancillary automation, factoring in longer lead times, recalibrated maintenance agreements, and the potential for increased spare parts costs. For reagent-intensive workflows, tariffs on raw materials and specialty enzymes have elevated attention on supply diversification, inventory hedging, and longer contract terms with suppliers who can guarantee continuity. In parallel, software and interpretive services, which are less dependent on cross-border physical shipments, have emerged as lower-tariff avenues to add value to diagnostic offerings and to offset hardware-related cost pressures.

Regulatory and procurement teams have responded by renegotiating supplier agreements, exploring strategic partnerships with regional manufacturers, and prioritizing open-platform instruments that accept a range of validated consumables to mitigate single-supplier risk. At the same time, laboratories have increased investments in workflow efficiency and multiplexing assays to reduce per-test reagent consumption. Collectively, these responses are reshaping purchasing patterns, driving more collaborative supplier relationships, and accelerating adoption of resilient procurement practices that balance cost, performance, and supply chain security under a more protectionist trade environment.

Unpacking detailed segmentation across product, technology, animal type, disease focus, and end-user settings to guide targeted diagnostic strategies and development

A nuanced understanding of market segmentation reveals where demand originates, how technology choices intersect with animal species and disease priorities, and which end-user settings will drive sustained adoption. Based on product distinctions, the market comprises consumables and reagents, instruments, and software and services. Consumables and reagents can be understood through their enzyme formulations, assay kits, and probes and primers that are critical for assay sensitivity and specificity, while instrument categories range from PCR instruments to sequencers that serve different throughput and application needs. Software and services increasingly function as the connective tissue that enables data interpretation, workflow orchestration, and remote diagnostics.

When viewed through the lens of technology, conventional PCR, digital PCR, isothermal amplification, microarray, next-generation sequencing, and real-time PCR present differentiated value propositions. Next-generation sequencing itself spans Illumina sequencing, Ion Torrent sequencing, and Oxford Nanopore approaches, each offering distinct trade-offs in read length, throughput, and field deployability. These technology choices map closely to animal type considerations where aquaculture testing for fish and shellfish requires robust, often field-capable assays; avian applications prioritize rapid pathogen detection to protect flock health; companion animal diagnostics, particularly for cats and dogs, emphasize genetic disorder screening and oncology panels; livestock testing for cattle, poultry, and swine centers on herd-level surveillance and production-impacting infectious diseases; and wildlife testing calls for broad-spectrum pathogen discovery and conservation-focused genetic analysis.

Disease-type segmentation further refines validation and development priorities, with genetic disorders necessitating high-fidelity genotyping assays, infectious diseases demanding sensitive and rapid pathogen detection across bacterial, fungal, parasitic, and viral etiologies, and oncology requiring assays that can profile tumor-associated variants. Finally, end users-academic institutes, diagnostic centers, reference laboratories, research institutes, and veterinary hospitals and clinics-differ in throughput, regulatory expectations, and willingness to adopt complex workflows. Academic and research settings often pilot innovative technologies and bioinformatics methods, reference laboratories prioritize standardized, high-throughput assays with rigorous QC, while clinical veterinary hospitals seek integrated solutions that deliver rapid, interpretable results to inform patient care. Taken together, these segmentation dimensions provide a roadmap for product development, validation strategies, and go-to-market prioritization that align technological capabilities with the operational needs of each user cohort.

Mapping regional demand drivers, infrastructure maturity, and regulatory diversity across the Americas, Europe Middle East Africa, and Asia-Pacific to inform deployment strategies

Regional dynamics play a decisive role in shaping demand, regulatory approaches, and deployment models for veterinary molecular diagnostics. In the Americas, a mature veterinary services market, robust research infrastructure, and advanced livestock and companion animal care ecosystems drive demand for high-throughput platforms, specialized reagents, and integrated software solutions that support both clinical decision-making and epidemiological surveillance. The region's strong base of private veterinary practices and reference labs also supports early adoption of novel assays and companion diagnostics tailored to companion animals and production species.

Across Europe, the Middle East and Africa, a diversity of regulatory environments and varying levels of laboratory capacity produce a heterogeneous adoption pattern. Western and northern European markets tend to adopt high-complexity technologies with stringent validation standards, while parts of the Middle East and Africa emphasize cost-effective, field-ready diagnostics to manage transboundary animal diseases and zoonotic risks. Capacity building and public-private partnerships are accelerating molecular diagnostic deployment in several subregions, supported by collaborative initiatives that strengthen laboratory networks and data-sharing frameworks.

The Asia-Pacific region is characterized by rapidly expanding veterinary services, sizable aquaculture industries, and intensive livestock production systems that heighten demand for scalable diagnostics and surveillance tools. Countries in this region are investing in sequencing and multiplex assay capabilities to manage disease outbreaks and to enhance food safety. Regional manufacturing capability and growing local reagent supply chains are also emerging, which helps mitigate the effects of cross-border trade disruptions and supports faster turnaround times for high-volume testing needs. These regional contrasts underscore the importance of tailoring product portfolios, regulatory strategies, and distribution models to localized clinical needs, infrastructure maturity, and policy priorities.

Assessing competitive dynamics and partnership-driven differentiation among instrument providers, reagent manufacturers, assay developers, and software service vendors

Competitive dynamics in veterinary molecular diagnostics reflect a mix of established platform providers, specialized assay developers, and agile startups that focus on niche applications or field-deployable technologies. Instrument manufacturers continue to invest in open-platform compatibility to capture consumable and service revenue streams, while reagent suppliers emphasize validated kits and quality control materials that accelerate laboratory accreditation and routine use. At the same time, software vendors and service providers are differentiating through analytics, interpretive algorithms, and cloud-enabled reporting that reduce the burden on end-user laboratories and clinicians.

Collaboration remains an important strategy: co-development agreements between assay developers and instrument providers accelerate validation cycles and enable bundled offerings that appeal to diagnostic centers and reference laboratories. Partnerships with academic institutions and research institutes often underpin innovation in assay design and bioinformatics pipelines, producing early-stage validation data that de-risks commercial launches. Startups focusing on point-of-care and portable sequencing are attracting attention for their potential to decentralize testing in aquaculture, livestock field surveillance, and wildlife monitoring, prompting strategic responses from incumbents seeking to fortify their product pipelines.

Finally, differentiation through quality, regulatory compliance, and customer support is increasingly significant. Buyers prioritize partners who can provide comprehensive training, robust QC materials, and rapid service response to minimize downtime. Companies that invest in lifecycle services, remote troubleshooting, and evidence-backed performance claims are better positioned to secure long-term contracts with diagnostic centers and veterinary hospital networks. In this competitive landscape, thoughtful alliance-building, clear validation pathways, and a focus on end-user experience determine which organizations capture the most durable value.

Prioritized, practical strategies for industry leaders to enhance resilience, accelerate clinical adoption, and expand diagnostic impact across animal health sectors

Industry leaders should pursue a set of practical, prioritized actions to strengthen resilience, accelerate adoption, and support clinical impact in veterinary molecular diagnostics. First, design product portfolios with interoperability in mind by validating assays across multiple instrument platforms and ensuring compatibility with widely used data management systems; this reduces procurement friction and expands addressable markets. Second, invest in regional manufacturing and strategic supplier agreements to secure critical reagents and enzymes, while implementing inventory optimization techniques to buffer short-term trade disruptions.

Third, align regulatory and clinical validation strategies to the needs of target end users by generating robust performance data for prioritized disease panels and species-specific indications. Engage early with reference laboratories and academic partners to co-develop evidence packages that facilitate adoption in diagnostic centers and clinical settings. Fourth, enhance service offerings by bundling software, interpretive analytics, and training programs that lower the operational barriers for veterinary hospitals and clinics adopting molecular diagnostics. Fifth, adopt modular go-to-market models that pair high-throughput reference lab solutions with scaled-down, field-capable platforms for aquaculture, livestock, and wildlife surveillance.

Finally, prioritize data governance, cybersecurity, and interoperability standards when designing cloud-based reporting systems, and maintain transparent communication about validation, quality control, and supply chain provenance. By executing these targeted actions, companies can reduce commercial friction, support evidence-based adoption, and create durable partnerships with laboratories and clinical networks that accelerate the uptake of molecular diagnostics across animal health domains.

Describing a rigorous mixed-methods research approach that synthesizes primary interviews, technical literature, and supply chain benchmarking to validate insights

This research integrates qualitative and quantitative methods to ensure a robust, evidence-based understanding of the veterinary molecular diagnostics landscape. The methodological approach began with a comprehensive review of peer-reviewed literature, regulatory guidance, technical white papers, and industry publications to establish baseline definitions, technology capabilities, and validation criteria. Building on this foundation, primary research included structured interviews with laboratory directors, veterinary clinicians, assay developers, instrument engineers, and procurement specialists to capture practical insights on workflow, adoption barriers, and purchasing behavior.

Additionally, a systematic mapping of product and technology segmentation was performed to align consumable categories, instrument classes, and software offerings with species-specific and disease-focused use cases. Cross-validation exercises compared primary insights with secondary sources and subject matter expert feedback to reconcile divergent perspectives and ensure internal consistency. Analytical techniques included thematic synthesis for qualitative inputs, workflow and use-case benchmarking to assess operational fit, and supply chain analysis to identify risk nodes and mitigation strategies.

Limitations are acknowledged: evolving trade policy, rapid platform innovations, and localized regulatory shifts can change dynamics after data collection, so stakeholders should treat findings as a decision-support framework rather than a static prediction. To support transparency, the methodology documents sources of primary data, interviewee profiles, and validation steps to allow readers to assess the applicability of specific findings to their contexts. This mixed-methods approach provides a defensible basis for strategic decisions, product planning, and regulatory engagement in the veterinary molecular diagnostics domain.

Concluding synthesis that emphasizes aligning technological innovation, operational resilience, and collaborative partnerships to realize durable diagnostic impact

The trajectory of veterinary molecular diagnostics is characterized by growing technical sophistication, heightened integration of data-driven services, and evolving procurement and regulatory landscapes that together create both opportunities and responsibilities for stakeholders. Across technologies and animal types, there is a clear movement toward solutions that balance analytical performance with operational feasibility, enabling faster, more accurate outcomes for clinical care, surveillance, and research. At the same time, supply chain vulnerabilities and tariff-related pressures necessitate strategic planning to ensure continuity of testing and maintain service levels across diverse end-user environments.

Consequently, organizations that invest in interoperable platforms, diversified supply chains, and evidence-led validation will be best positioned to support the expanding role of molecular diagnostics in veterinary medicine. Equally important is the commitment to end-user training, quality assurance, and data stewardship to translate analytical gains into improved animal health outcomes. The conclusion synthesizes the core message: sustainable progress depends on aligning technological innovation with pragmatic deployment strategies, robust partnerships, and adaptive procurement practices that together enable scalable, high-quality diagnostic services across the full spectrum of veterinary care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of next-generation sequencing for rapid pathogen detection in veterinary diagnostics
  • 5.2. Expansion of point-of-care PCR assays for on-site disease screening in livestock and companion animals
  • 5.3. Adoption of digital PCR technologies to quantify viral load in animal health monitoring
  • 5.4. Use of CRISPR-based diagnostic tools for ultrasensitive detection of zoonotic pathogens
  • 5.5. Development of multiplex molecular panels for simultaneous detection of multiple veterinary pathogens
  • 5.6. Incorporation of AI-driven data analytics to enhance interpretation of molecular diagnostic results
  • 5.7. Emergence of portable isothermal amplification devices for field-ready molecular testing in veterinary settings
  • 5.8. Growth of tele-diagnostics services leveraging molecular assays for decentralized veterinary care
  • 5.9. Implementation of molecular biomarkers for early detection of antimicrobial resistance in animal pathogens
  • 5.10. Collaboration between veterinary diagnostic laboratories and biotech firms to accelerate assay development and validation

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Veterinary Molecular Diagnostic Market, by Product

  • 8.1. Consumables & Reagents
    • 8.1.1. Enzymes
    • 8.1.2. Kits
    • 8.1.3. Probes & Primers
  • 8.2. Instruments
    • 8.2.1. PCR Instruments
    • 8.2.2. Sequencers
  • 8.3. Software & Services

9. Veterinary Molecular Diagnostic Market, by Technology

  • 9.1. Conventional PCR
  • 9.2. Digital PCR
  • 9.3. Isothermal Amplification
  • 9.4. Microarray
  • 9.5. Next-Generation Sequencing
    • 9.5.1. Illumina Sequencing
    • 9.5.2. Ion Torrent Sequencing
    • 9.5.3. Oxford Nanopore
  • 9.6. Real-Time PCR

10. Veterinary Molecular Diagnostic Market, by Animal Type

  • 10.1. Aquaculture
    • 10.1.1. Fish
    • 10.1.2. Shellfish
  • 10.2. Avian
  • 10.3. Companion Animals
    • 10.3.1. Cats
    • 10.3.2. Dogs
  • 10.4. Livestock
    • 10.4.1. Cattle
    • 10.4.2. Poultry
    • 10.4.3. Swine
  • 10.5. Wildlife

11. Veterinary Molecular Diagnostic Market, by Disease Type

  • 11.1. Genetic Disorders
  • 11.2. Infectious Diseases
    • 11.2.1. Bacterial Infections
    • 11.2.2. Fungal Infections
    • 11.2.3. Parasitic Infections
    • 11.2.4. Viral Infections
  • 11.3. Oncology

12. Veterinary Molecular Diagnostic Market, by End User

  • 12.1. Academic Institutes
  • 12.2. Diagnostic Centers
  • 12.3. Reference Laboratories
  • 12.4. Research Institutes
  • 12.5. Veterinary Hospitals & Clinics

13. Veterinary Molecular Diagnostic Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Veterinary Molecular Diagnostic Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Veterinary Molecular Diagnostic Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. IDEXX Laboratories, Inc.
    • 16.3.2. Thermo Fisher Scientific Inc.
    • 16.3.3. Zoetis Inc.
    • 16.3.4. QIAGEN N.V.
    • 16.3.5. Bio-Rad Laboratories, Inc.
    • 16.3.6. Neogen Corporation
    • 16.3.7. Heska Corporation
    • 16.3.8. Ceva Sante Animale S.A.
    • 16.3.9. Vetoquinol S.A.
    • 16.3.10. Eurofins Scientific SE

LIST OF FIGURES

  • FIGURE 1. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. VETERINARY MOLECULAR DIAGNOSTIC MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. VETERINARY MOLECULAR DIAGNOSTIC MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. VETERINARY MOLECULAR DIAGNOSTIC MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CONSUMABLES & REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CONSUMABLES & REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CONSUMABLES & REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CONSUMABLES & REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CONSUMABLES & REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CONSUMABLES & REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CONSUMABLES & REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ENZYMES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ENZYMES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ENZYMES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ENZYMES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ENZYMES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ENZYMES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PROBES & PRIMERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PROBES & PRIMERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PROBES & PRIMERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PROBES & PRIMERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PROBES & PRIMERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PROBES & PRIMERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PCR INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PCR INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PCR INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PCR INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PCR INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PCR INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SEQUENCERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SEQUENCERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SEQUENCERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SEQUENCERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SEQUENCERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SEQUENCERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CONVENTIONAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CONVENTIONAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CONVENTIONAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CONVENTIONAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CONVENTIONAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CONVENTIONAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DIGITAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY MICROARRAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY MICROARRAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ILLUMINA SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ILLUMINA SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ILLUMINA SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ILLUMINA SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ILLUMINA SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ILLUMINA SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ION TORRENT SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ION TORRENT SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ION TORRENT SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ION TORRENT SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ION TORRENT SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ION TORRENT SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY OXFORD NANOPORE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY OXFORD NANOPORE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY OXFORD NANOPORE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY OXFORD NANOPORE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY OXFORD NANOPORE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY OXFORD NANOPORE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY REAL-TIME PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY REAL-TIME PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY REAL-TIME PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY REAL-TIME PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY AQUACULTURE, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY AQUACULTURE, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY AQUACULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY AQUACULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY AQUACULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY AQUACULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY AQUACULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY AQUACULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY FISH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY FISH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY FISH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY FISH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY FISH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY FISH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SHELLFISH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SHELLFISH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SHELLFISH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SHELLFISH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SHELLFISH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SHELLFISH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY AVIAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY AVIAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY AVIAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY AVIAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY AVIAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY AVIAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CATS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CATS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CATS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CATS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CATS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CATS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DOGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DOGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DOGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DOGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DOGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DOGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY LIVESTOCK, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY LIVESTOCK, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY LIVESTOCK, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY LIVESTOCK, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY LIVESTOCK, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY LIVESTOCK, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CATTLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CATTLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CATTLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CATTLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CATTLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CATTLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY POULTRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY POULTRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY POULTRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY POULTRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY POULTRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY POULTRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SWINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SWINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SWINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SWINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SWINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SWINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY WILDLIFE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY WILDLIFE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY WILDLIFE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY WILDLIFE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY WILDLIFE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY WILDLIFE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY GENETIC DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY GENETIC DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY GENETIC DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY GENETIC DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ACADEMIC INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ACADEMIC INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ACADEMIC INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ACADEMIC INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CONSUMABLES & REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION